ondasdechoque.org
PT-BR

Chronic low-back pain: pooled results need reconciliation · Review · 2023

Does shockwave help chronic low-back pain and daily function?

In this review of 12 trials (632 people), pain scores were about 1 point lower with shockwave than with comparison treatments at 4 weeks. In the 5 trials that went on to 12 weeks, pain was still lower on average with shockwave. Disability scores were also a little lower at both times.

Helped a little more than comparison care at 4 weeks
trials
12
adults with long-lasting low-back pain
632
weeks: the longest follow-up pooled
12

Good to know: Trials varied in devices, doses and comparisons; results were pooled at 4 and 12 weeks.

Liu K, Zhang Q, Chen L, et al. J Orthop Surg Res, 2023 · Read the paper ↗

How this study worked

12 studies632 peopleOne answer
A review gathers earlier studies to answer one question.

What happened

studies
12
people
632
Compared with
Exercise, physical therapies, trigger-point injections, medicines, myofascial treatment or sham with exercise, depending on the trial

Low-back pain compared with other treatments

Difference in pain-scale points · below zero means less pain with shockwave

Across 12 trials, pain was about 1 point lower with shockwave than with comparison treatments at 4 weeks.
Show the numbers
Difference (pain-scale points)likely range
Pain at 4 weeks−1.04−1.44 to −0.65

What the trials used

Protocol variety
Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.

Who took part

632 adults with long-lasting low-back pain from muscle, joint or other mechanical causes; people after surgery, during pregnancy or with serious spine disease were excluded.

Side effects

Seven trials reported no side effects and five did not record them. No serious problems were reported.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with mechanical chronic low-back pain; varied causes included quadratus-lumborum trigger points and sacroiliac pain. Total 318 ESWT/314 controls, but outcome-specific totals differ. Postoperative, pregnancy and specific serious spinal disorders excluded.

Pain at 4 weeks1 reported outcome
01
Four weeks

Pain at 4 weeks

Pain at 4 weeks VAS points

MD-1.04CI 95% -1.44 to -0.65p <0.00001

ESWT versus study-specific controls

12 studies · 632 participants in this estimate · I²=86%

Pooled random-effects estimate

-1.6Equal results 00.2

The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.

Analysis details and source

Figure 3 reverses Guo/Taheri sample sizes relative to Table 1; the Jin 2017 report is nonrandomized despite the RCT label.

Pain at 12 weeks1 reported outcome
02
Twelve weeks

Pain at 12 weeks

Pain at 12 weeks VAS points

MD-0.85CI 95% -1.3 to -0.41p = 0.0001

ESWT versus study-specific controls

5 studies · 230 participants in this estimate · I²=87%

Figure labels fixed effects; text claims random effects.

-1.5Equal results 00.2

The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.

Analysis details and source

Figure 4 labels fixed effects despite text claiming random effects; I²=87%. The review's own sensitivity plot for these five trials (Fig. 8a) is centered on −1.31 with limits −2.70 and 0.09, an interval that crosses zero; a random-effects re-analysis of the Fig. 4 trial data gives the same values. The stored −0.85 (−1.30 to −0.41) is the printed fixed-effect result.

ODI at 4 weeks1 reported outcome
03
Four weeks

ODI at 4 weeks

ODI at 4 weeks ODI points

MD-4.22CI 95% -7.55 to -0.89p = 0.01

ESWT versus study-specific controls

10 studies · 513 participants in this estimate · I²=96%

Pooled random-effects estimate

-8.5Equal results 00.9

The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.

Analysis details and source

Figure/text p=.01 differs from abstract p<.001; I²=96%.

ODI at 12 weeks1 reported outcome
04
Twelve weeks

ODI at 12 weeks

ODI at 12 weeks ODI points

MD-4.51CI 95% -8.58 to -0.44p = 0.03

ESWT versus study-specific controls

4 studies · 139 participants in this estimate · I²=56%

Pooled random-effects estimate

-9.6Equal results 01

The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.

Analysis details and source

Substantial heterogeneity (I²=56%) and only four reports limit precision and generalizability.

Mental health1 reported outcome
05
Four weeks

Mental health

Mental health standard deviations

SMD1.17CI 95% -0.1 to 2.45p = 0.07

ESWT versus study-specific controls

5 studies · 405 participants in this estimate · I²=96%

Pooled random-effects estimate

-0.4Equal results 02.8

The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.

Analysis details and source

Opposing scale directions are not transparently harmonized; I²=96% and the confidence interval crosses zero.

Important null subgroups1 reported outcome
06
Four weeks

Important null subgroups

Qualitative finding

Pain vs trigger-point injection at 4 weeks MD −0.99 [−2.36, 0.38], p = 0.16; ODI vs physiotherapy at 4 weeks MD −2.35 [−10.89, 6.18], p = 0.59; ODI vs myofascial therapy at 4 weeks MD 3.30 [−0.56, 7.16], p = 0.09.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
Protocol variety

Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.

HARMS & TOLERABILITY

Seven studies explicitly reported no adverse reactions; five did not record them. No serious event was reported, but nonreporting cannot establish safety or no increased risk.

LIMITS OF THE ANALYSIS

High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.
Research review

Source-linked critical reading

clinical synthesis

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Review of 12 reports labelled RCTs, 632 participants, four databases to 25 April 2023; PROSPERO CRD42023421589. Pooling selected observations nearest 4 and 12 weeks. Design labels and analytic consistency require verification.

Participants and setting

Adults with mechanical chronic low-back pain; varied causes included quadratus-lumborum trigger points and sacroiliac pain. Total 318 ESWT/314 controls, but outcome-specific totals differ. Postoperative, pregnancy and specific serious spinal disorders excluded.

Treatment

Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.

Comparison

Exercise, physical modalities, trigger-point injection, oral medicines and myofascial treatment; some trials used sham plus shared exercise. These control strategies are not interchangeable.

Outcomes and timing

Pain VAS and ODI at 4/12 weeks; SF-36, PHQ-9 or BDI pooled as mental health at 4 weeks. Higher-is-better and lower-is-better scales require direction harmonization not transparently demonstrated.

What the results show

Pain MD −1.04 (95% CI −1.44 to −.65) at 4 weeks and −.85 (−1.30 to −.41) at 12 weeks. ODI −4.22 (−7.55 to −.89) and −4.51 (−8.58 to −.44). Mental health SMD 1.17 (−.10 to 2.45), p=.07. Injection subgroup pain and physiotherapy subgroup ODI were null.

Harms

Seven studies explicitly reported no adverse reactions; five did not record them. No serious event was reported, but nonreporting cannot establish safety or no increased risk.

Limits and disclosures

High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.

Application to care

Possible short-term benefits require reanalysis with verified trial identity and consistent models. The review cannot establish durable benefit, optimal modality or a mental-health effect.

What remains to be tested

Reconcile trial labels and denominators, remove nonrandomized reports from RCT-only synthesis, harmonize mental-health scales and prespecify outcome timepoints and models.

THE ORIGINAL SOURCE

Read the original article.

Efficacy and safety of extracorporeal shockwave therapy in chronic low back pain: a systematic review and meta-analysis of 632 patients

Liu K, Zhang Q, Chen L, Zhang H, Xu X, Yuan Z, Dong J. · J Orthop Surg Res · 2023

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →